Drug discovery and development: introduction to the general public and patient groups

• Published in: Frontiers in Drug Discovery
• Main Authors: Natesh Singh, Philippe Vayer, Shivalika Tanwar, Jean-Luc Poyet, Katya Tsaioun, Bruno O. Villoutreix
• Format: Article
• Language: English
• Published: Frontiers Media S.A. 2023-05-01
• Subjects: drug discovery; drug development; therapeutic agent; biologics; small molecules; artificial intelligence (AI)
• Online Access: https://www.frontiersin.org/articles/10.3389/fddsv.2023.1201419/full

Finding new drugs usually consists of five main stages: 1) a pre-discovery stage in which basic research is performed to try to understand the mechanisms leading to diseases and propose possible targets (e.g., proteins); 2) the drug discovery stage, during which scientists search for molecules (two main large families, small molecules and biologics) or other therapeutic strategies that interfere or cure the investigated disease or at least alleviate the symptoms; 3) the preclinical development stage that focuses on clarifying the mode of action of the drug candidates, investigates potential toxicity, validates efficacy on various in vitro and in vivo models, and starts evaluate formulation; 4) the clinical stage that investigates the drug candidate in humans; 5) the reviewing, approval and post-market monitoring stage during which the drug is approved or not. In practice, finding new treatments is very challenging. Despite advances in the understanding of biological systems and the development of cutting-edge technologies, the process is still long, costly with a high attrition rate. New approaches, such as artificial intelligence and novel in vitro technologies, are being used in an attempt to rationalize R&D and bring new drugs to patients faster, but several obstacles remain. Our hope is that one day, it becomes possible to rapidly design inexpensive, more specific, more effective, non-toxic, and personalized drugs. This is a goal towards which all authors of this article have devoted most of their careers.